Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Apr 22, 2021As part of its 2030+ sustainability goals, BD pledges carbon neutrality by 2040 across direct operationsIn recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming...
Apr 20, 2021BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator (2% w/w...
-
Apr 20, 2021Company continues its commitment to expanding health care access through its long-standing support of UNICEF USA and their efforts to eliminate Maternal and Neonatal Tetanus
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $1 million commitment over five years to UNICEF USA in support of UNICEF's work to...
Apr 14, 2021Clearance supported by clinical data from a feasibility study with favorable primary patency rates observed out to 180 daysBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for...
Apr 13, 2021WHO Rapid Communication cites high accuracy for the detection of TB, rifampicin and isoniazid resistance on respiratory samplesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was...
-
Apr 5, 2021
BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021. BD will issue a press...
-
Apr 1, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona...
Apr 1, 2021BD Veritor™ Plus System supports return-to-school and return-to-work programs through serial testingBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization...
Mar 30, 2021FRANKLIN LAKES, N.J. (March 30, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Brooke Story to the...
Mar 30, 2021New Test on the BD Veritor™ Plus System Can Detect SARS-CoV-2, Influenza A, Influenza B from Single Patient SampleBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA)...
-
Mar 24, 2021
BD (Becton, Dickinson and Company), a leading global medical technology company, has expanded a voluntary recall that was initiated on June 23, 2020 for specified catalog numbers of the...
Mar 17, 2021FRANKLIN LAKES, N.J. (March 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S....
Mar 9, 2021Reporting app helps facilitate SARS-CoV-2 testing and result reporting from BD Veritor™ Plus SystemBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with ImageMover, a software platform that automates and simplifies medical...
-
Mar 4, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc. ("GSL"), a privately-held company that develops...
-
Feb 22, 2021Aims to Pair BD Antigen Test with Scanwell Health Mobile App
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled at-home medical tests, today announced a...
-
Feb 17, 2021
FRANKLIN LAKES, N.J. (Feb. 17, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration’s...
-
Feb 12, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences: The...
Feb 12, 2021New single test for the BD MAX™ System also shows ability to detect U.K., South African VariantsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use...
Feb 8, 2021FRANKLIN LAKES, N.J. (Feb. 8, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dev Kurdikar, 52, to the...
-
Feb 4, 2021- First fiscal quarter revenues of $5.315 billion grew 25.8% on a reported basis. On a currency-neutral basis, revenues increased 24.3%.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31,...
Feb 3, 2021In conjunction with clinical findings and the results of other laboratory testing, BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes may help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in patient management decisionsEYSINS, Switzerland, (Feb. 3, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE mark of BD Multitest™ 6-Color TBNK...
Feb 2, 2021- There is robust evidence that the BD vascular care solution and skin antiseptic for peripheral intravenous catheters used in the CLEAN3 randomized clinical trial can help improve patient outcomesBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution...
Jan 26, 2021Polen to Succeed Vince Forlenza Effective April 28BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of...
-
Jan 25, 2021
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on March 31, 2021 to holders of record on March 10,...
Jan 25, 2021Peer-Reviewed Study Suggests BD Antigen Test Likely to Be More Selective at Detecting Patients Who Are Shedding Infectious SARS-CoV-2 VirusBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a peer-reviewed study that shows BD's antigen test may be more...